Vilitra 10 contains the active ingredient Vardenafil, which belongs to a class of medications known as phosphodiesterase type 5 (PDE5) inhibitors. These drugs work by blocking the action of PDE5 enzyme, which normally breaks down cyclic guanosine monophosphate (cGMP). By inhibiting PDE5, Vardenafil allows cGMP levels to increase, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum of the penis.
While Vilitra 10 mg primarily acts on the PDE5 enzyme, its effects on adrenergic receptors in the penis are indirect. Adrenergic receptors respond to neurotransmitters like adrenaline (epinephrine) and noradrenaline (norepinephrine). In the penis, adrenergic receptors play a role in regulating smooth muscle contraction and blood flow.
Vardenafil's inhibition of PDE5 indirectly affects adrenergic receptor activity by enhancing the effects of nitric oxide (NO), which is released in response to sexual stimulation. NO activates guanylate cyclase, leading to increased production of cGMP. Elevated cGMP levels then promote smooth muscle relaxation in the penis, allowing for increased blood flow and erection.
In summary, while Vilitra 10 primarily acts on PDE5, its mechanism of action indirectly influences adrenergic receptor activity in the penis by enhancing NO-mediated vasodilation and smooth muscle relaxation.
